Want to join the conversation?
Biotechnology company $BIIB said it has appointed Michel Vounatsos as EVP and Chief Commercial Officer effective April 18, 2016. Mr. Vounatsos will oversee the development and execution of $BIIB's global commercial strategy and he will report to CEO George Scangos. Mr. Vounatsos comes to $BIIB from Merck where he held various leadership positions.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.